Sep 20,2023

Artificial Intelligence and Diabetic Retinopathy: AI Framework, Prospective Studies, Head-to-head Validation, and Cost-effectiveness

The article titled "Artificial Intelligence and Diabetic Retinopathy" discusses the significant role of artificial intelligence (AI) algorithms in screening for diabetic retinopathy (DR), a leading cause of blindness in diabetic patients. It outlines the increasing global prevalence of diabetes and the imperative need for regular DR screenings. AI algorithms have been developed to autonomously analyze fundus photographs for signs of DR, achieving good sensitivity and specificity in detecting referable DR cases. The article explains the fundamental concepts of AI model development, data labeling, and training. Additionally, the article touches on the cost-effectiveness, equity, bias, and medicolegal considerations associated with AI implementation in clinical practice.

CLINICAL STUDY
View Analyst & Ambassador Comments
Go to original news
Nov 02,2019

metaMe Health Announces First Subject Enrolled in Pivotal Study of a Digital Therapeutic for Treatment of IBS

metaMe Health, Inc., a Chicago-based prescription digital therapeutics company committed to the treatment of gastrointestinal (GI) conditions such as Irritable Bowel Syndrome (IBS), today announced that the first subject has enrolled in a pivotal study to evaluate the efficacy and safety of an all-digital, self-administered behavioral therapy for the treatment of adult subjects with symptomatic IBS.  This trial is a randomized, controlled, parallel-group study that will enroll subjects from across the United States. metaMe expects to enroll approximately 380 patients, aged 18 years and older, to the study, in partnership with the digital clinicial trials company Curebase. Initial results are expected by the second half of 2020.

CLINICAL STUDY

#cbt

#mobile app

View Analyst & Ambassador Comments
Go to original news
Sep 08,2023 TOP STORY

Artificial intelligence for breast cancer detection in screening mammography in Sweden: a prospective, population-based, paired-reader, non-inferiority study

Artificial intelligence (AI) as an independent reader of screening mammograms has shown promise, but there are few prospective studies. The aim of this study was to conduct a prospective clinical trial to examine how AI affects cancer detection and false positive findings in a real-world setting. ScreenTrustCAD was a prospective, population-based, paired-reader, non-inferiority study done at the Capio Sankt Göran Hospital in Stockholm, Sweden. The primary outcome was screen-detected breast cancer within 3 months of mammography, and the primary analysis was to assess non-inferiority (non-inferiority margin of 0·15 relative reduction in breast cancer diagnoses) of double reading by one radiologist plus AI compared with standard-of-care double reading by two radiologists. From April 1, 2021, to June 9, 2022, 58?344 women aged 40–74 years underwent regular mammography screening, of whom 55?581 were included in the study. 269 (0·5%) women were diagnosed with screen-detected breast cancer based on an initial positive read: double reading by one radiologist plus AI was non-inferior for cancer detection compared with double reading by two radiologists. Single reading by AI and triple reading by two radiologists plus AI were also non-inferior to double reading by two radiologists.

CLINICAL STUDY

#ai/software

View Analyst & Ambassador Comments
Go to original news
Aug 31,2023

AI Predictions for Colorectal Cancer: One Step Closer to Efficient Precision Oncology

Colorectal cancer (CRC) ranks second in leading causes of cancer-related deaths globally, according to the WHO. For the first time, researchers from Helmholtz Munich and the University of Technology Dresden (TU Dresden) show that artificial intelligence (AI)-based predictions can deliver comparable results to clinical tests on biopsies of patients with CRC. This novel model for biomarker detection represents a significant stride towards the realization of precision therapy approaches in the field of oncology. The method is now published in Cancer Cell. A team of scientists around Dr. Tingying Peng from Helmholtz Munich and Prof. Jakob N. Kather from TU Dresden show that AI can predict specific biomarkers in stained tissue samples of patients with CRC. They used so-called transformer networks, a recent deep learning (DL) approach, to identify patterns and support diagnostic decisions in cancer management. The new method significantly improves previous approaches for biomarker detection.

CLINICAL STUDY

#ai/software

#ml

View Analyst & Ambassador Comments
Go to original news
Aug 30,2023

Combining AI Models Improves Breast Cancer Risk Assessment

Combining artificial intelligence (AI) systems for short- and long-term breast cancer risk results in an improved cancer risk assessment, according to a study published in Radiology, a journal of the Radiological Society of North America (RSNA). For this study, Dr. Lauritzen and his research team sought to identify whether a commercially available diagnostic AI tool and an AI texture model, trained separately and then subsequently combined, may improve breast cancer risk assessment. The researchers used the diagnostic AI tool Transpara and a texture model that was developed by the researchers. A Dutch training set of over 39,000 exams was used to train the models. The short- and long-term risk models were combined using a three-layer neural network. Compared to the diagnostic and texture models alone, the combined AI model showed an overall improved risk assessment for both interval and long-term cancer detection. Interval cancers are those that are found between routine screenings. The model also enabled identification of women at high risk for breast cancer.

CLINICAL STUDY

#ai/software

View Analyst & Ambassador Comments
Go to original news
Sep 12,2023

New Study Evaluates How Quickly the Migraine Preventive Impact of Nerivio® Starts

Theranica, a neuromodulation therapeutics company, announced the results of a study recently published in Pain Management, suggesting the rapid impact of Nerivio, the first and only migraine neuroband, in reducing the number of migraine days. A previous study has already shown that using Nerivio every other day for 8 weeks reduces the mean number of migraine days per month by 4.0 days (compared to 1.3 days in the placebo group). The study (NCT04828707) was a prospective, randomized, double-blind, placebo-controlled clinical trial that evaluated the efficacy of REN treatment applied every other day for the prevention of migraine. The trial included a 4-week baseline (observation) phase and an 8-week double-blind intervention phase. The number of monthly migraine days (MMD) per group was calculated in two-week intervals and compared between the groups. The new study was a post-hoc analysis of that study, evaluating the preventive response at time points earlier than 8 weeks. The findings were that, already after two weeks of usage, there was a statistically significant mean reduction of 1.7 migraine days per month, compared to 0.8 days in the placebo group

CLINICAL STUDY

#connected device

#pdt

View Analyst & Ambassador Comments
Go to original news
Jul 12,2021

Research shows how Constant Therapy helps people living with dementia

This two-patient case study sought to determine the efficacy of Constant Therapy as an intervention for persons with dementia. Edgar and Bargmann retrospectively analyzed the progress of two patients who had been previously diagnosed with Alzheimer’s disease and vascular dementia, respectively. Both participants demonstrated strong improvement overall. They also both exhibited carry-over with skills used in reading, spelling and listening comprehension. As a result, both participants experienced better self-confidence and a sense of improvement. Edgar and Bargmann found that the frequency of Constant Therapy use correlated with the mastery of assigned exercises. This finding is significant because it shows that Constant Therapy can be used not just to prevent further decline of cognitive and language skills, but also to improve existing ones.

CLINICAL STUDY

#mobile app

View Analyst & Ambassador Comments
Go to original news
Jul 20,2022

Constant Therapy Announces Publication of Study Demonstrating Improved Outcomes for Post-Stroke Patients Using Its Digital Speech, Language, and Cognitive Therapy

Constant Therapy Health, a brain health digital therapeutics company, announced today the publication of a dosage study in the Journal of Medical Internet Research entitled, “Dosage Frequency Effects on Treatment Outcomes Following Self-managed Digital Therapy: Retrospective Cohort Study”. The study, conducted by a Boston University Research Team led by Dr. Swathi Kiran, analyzed data from Constant Therapy’s mobile speech, language, and cognitive therapy program. The findings determined the optimal dosage frequency for self-managed digital cognitive and speech therapy and demonstrated that increased dosage frequency is associated with better therapy outcomes for individuals with post-stroke speech, language, and/or cognitive disorders.

CLINICAL STUDY

#mobile app

View Analyst & Ambassador Comments
Go to original news
Sep 12,2022

Research using Constant Therapy mentioned in Neurology Live

Constant Therapy Health, a brain health digital therapeutics company, announced today the publication of a feasibility study of its Constant Therapy digital cognitive therapy platform in the Journal of Medical Internet Research (JMIR) titled, “Home-Based Electronic Cognitive Therapy in Patients With Alzheimer Disease: Feasibility Randomized Controlled Trial.” The study included a total of 19 patients all between the ages of 50 and 90 years of age with a diagnosis of mild cognitive impairment (MCI) secondary to Alzheimer’s disease or mild Alzheimer’s dementia, who were randomized into the experimental group which used Constant Therapy, or the active control group, which did paper and pencil games. Patients were assessed using the Repeatable Battery for the Assessment of Neuropsychological Status (RBANS) every 6 weeks. Feasibility analyses were computed for participants who completed 24 weeks of Constant Therapy and found that long-term use of the Constant Therapy program was feasible using it for about 32 minutes daily with an adherence rate of 80 percent (121 out of 168 days). These participants showed an overall improvement in accuracy and latency (P=.005) in the Constant Therapy scores, as well as specific improvements in tasks of visual and auditory memory, attention, and arithmetic.

CLINICAL STUDY

#mobile app

View Analyst & Ambassador Comments
Go to original news
May 21,2019

Medisafe Presents Results of Study on Chronically Non-Adherent Patients

The study used retrospective patient data from Medisafe linked anonymously to IQVIA’s longitudinal prescription claims database (LRx). The findings showed clinically and statistically meaningful results across two standard healthcare industry adherence metrics: MPR, which tracks frequency of refill, where an MPR of 1.0 corresponds to a 100% timely refill rate; and persistence, which measures duration of therapy (without refill gaps). Hypertension, diabetes and depression patients increased their mean MPR from below 0.6 before using Medisafe (“pre-app”) to above 0.9 after using Medisafe (“post-app”). Additionally, almost 70% of non-adherent patients (MPR <.8) pre-app became adherent post-app.

CLINICAL STUDY

#mobile app

View Analyst & Ambassador Comments
Go to original news
Subscribe to CLINICAL STUDY